Ticagrelor
ticagrelor is a selective Adenosine Diphosphate receptor antagonist, its act on PZY12 ADP receptor that prevent ADP mediated platelet activation and aggregation. Ticagrelor is orally active, and reversibly bind to platelet PZY12 ADP receptor to prevent signal transduction.
Primary Characteristics
It belongs to cyclopentyltriazolopyrimidines.
It belongs to Adinosine Diphosphate Receptor Antagonist pharmacological group on the basis of mechanism of action.
Non-proprietary name: Ticagrelor.
Pharmacokinetics
Absorption: Ticagrelor has an oral bioavailability is 18% (±18%).
Distribution: Ticagrelor has a volume of distribution is 87.51L. plasma protein binding is 99.7%.
Elimination: it is metabolised via hepatic, plasma half-life is 7 hours.
Advertisement
Indications
Ticagrelor is primarily indicated in conditions like atherothrombotic event.
Contraindications
Ticagrelor is contraindicated in conditions like Hepatic impairment, Hypersensitivity, Bleeding, Severe renal impairment.
Dosage
Ticagrelor's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 135 mg | 135 mg | Every 24h | PO | initially 180mg loading dose , then 90 mg BID for 12 months |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
The signs and symptoms that are produced after acute overdosage of Ticagrelor are Dyspnea, GI toxicity, ventricular pauses.
Ticagrelor is known to cause more or less tolerable side effects which are usually transient. These include dermal bleeding, Dyspnea, Epistaxis, GI hemorrhage, Hyperuricemia , Intracranial hemorrhage.
Warnings / Precautions
Available Brands
None recorded.
Drug Classification
- 1.10.2 — Anticoagulants/Platelet deaggregators